306 related articles for article (PubMed ID: 30509962)
21. Slow N-acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity.
Ohno M; Yamaguchi I; Yamamoto I; Fukuda T; Yokota S; Maekura R; Ito M; Yamamoto Y; Ogura T; Maeda K; Komuta K; Igarashi T; Azuma J
Int J Tuberc Lung Dis; 2000 Mar; 4(3):256-61. PubMed ID: 10751073
[TBL] [Abstract][Full Text] [Related]
22. Risk factors of isoniazid-induced hepatotoxicity in Tunisian tuberculosis patients.
Ben Fredj N; Gam R; Kerkni E; Chaabane A; Chadly Z; Boughattas N; Aouam K
Pharmacogenomics J; 2017 Jul; 17(4):372-377. PubMed ID: 27089936
[TBL] [Abstract][Full Text] [Related]
23. NAT2 polymorphisms and susceptibility to anti-tuberculosis drug-induced liver injury: a meta-analysis.
Wang PY; Xie SY; Hao Q; Zhang C; Jiang BF
Int J Tuberc Lung Dis; 2012 May; 16(5):589-95. PubMed ID: 22409928
[TBL] [Abstract][Full Text] [Related]
24. Role of polymorphic N-acetyl transferase2 and cytochrome P4502E1 gene in antituberculosis treatment-induced hepatitis.
Bose PD; Sarma MP; Medhi S; Das BC; Husain SA; Kar P
J Gastroenterol Hepatol; 2011 Feb; 26(2):312-8. PubMed ID: 21261721
[TBL] [Abstract][Full Text] [Related]
25. Association between TXNRD1 polymorphisms and anti-tuberculosis drug-induced hepatotoxicity in a prospective study.
Ji GY; Wang Y; Wu SQ; Liu QQ; Wu JC; Zhang MM; Sandford AJ; He JQ
Genet Mol Res; 2016 Sep; 15(3):. PubMed ID: 27706680
[TBL] [Abstract][Full Text] [Related]
26. NAT2 6A, a haplotype of the N-acetyltransferase 2 gene, is an important biomarker for risk of anti-tuberculosis drug-induced hepatotoxicity in Japanese patients with tuberculosis.
Higuchi N; Tahara N; Yanagihara K; Fukushima K; Suyama N; Inoue Y; Miyazaki Y; Kobayashi T; Yoshiura K; Niikawa N; Wen CY; Isomoto H; Shikuwa S; Omagari K; Mizuta Y; Kohno S; Tsukamoto K
World J Gastroenterol; 2007 Dec; 13(45):6003-8. PubMed ID: 18023090
[TBL] [Abstract][Full Text] [Related]
27. Genetic polymorphisms of NAT2 and CYP2E1 associated with antituberculosis drug-induced hepatotoxicity in Korean patients with pulmonary tuberculosis.
Cho HJ; Koh WJ; Ryu YJ; Ki CS; Nam MH; Kim JW; Lee SY
Tuberculosis (Edinb); 2007 Nov; 87(6):551-6. PubMed ID: 17950035
[TBL] [Abstract][Full Text] [Related]
28. Pharmacogenetics of isoniazid-induced hepatotoxicity.
Perwitasari DA; Atthobari J; Wilffert B
Drug Metab Rev; 2015 May; 47(2):222-8. PubMed ID: 26095714
[TBL] [Abstract][Full Text] [Related]
29. Association of NAT2, GST and CYP2E1 polymorphisms and anti-tuberculosis drug-induced hepatotoxicity.
Singla N; Gupta D; Birbian N; Singh J
Tuberculosis (Edinb); 2014 May; 94(3):293-8. PubMed ID: 24637014
[TBL] [Abstract][Full Text] [Related]
30. [Tuberculosis: relevance of isoniazid dosage in prevention of liver side effects].
Negri L; Le Grusse J; Séraissol P; Lavit M; Houin G; Gandia P
Therapie; 2014; 69(6):509-16. PubMed ID: 25314930
[TBL] [Abstract][Full Text] [Related]
31. Susceptibility of N-acetyltransferase 2 slow acetylators to antituberculosis drug-induced liver injury: a meta-analysis.
Shi J; Xie M; Wang J; Xu Y; Liu X
Pharmacogenomics; 2015 Dec; 16(18):2083-97. PubMed ID: 26616266
[TBL] [Abstract][Full Text] [Related]
32. Association of CYP2B6 gene polymorphisms and anti-tuberculosis drug-induced hepatotoxicity in a Chinese population.
Wang Y; Xiang X; Wu SQ; Chen G; Zhang MM; Wang MG; Wang FJ; Sandford AJ; He JQ
Infect Genet Evol; 2017 Jul; 51():198-202. PubMed ID: 28389387
[TBL] [Abstract][Full Text] [Related]
33. NAT2 and CYP2E1 polymorphisms and susceptibility to first-line anti-tuberculosis drug-induced hepatitis.
Lee SW; Chung LS; Huang HH; Chuang TY; Liou YH; Wu LS
Int J Tuberc Lung Dis; 2010 May; 14(5):622-6. PubMed ID: 20392357
[TBL] [Abstract][Full Text] [Related]
34. [The associations of polymorphism of N-acetyltransferase 2 gene is associated with antituberculosis drug-induced hepatotoxicity in tuberculosis patients].
An HR; Wu XQ; Wang ZY; Liang Y; Zhang JX
Zhonghua Yu Fang Yi Xue Za Zhi; 2011 Jan; 45(1):36-40. PubMed ID: 21418817
[TBL] [Abstract][Full Text] [Related]
35. Factors associated with anti-TB drug-induced hepatotoxicity and genetic polymorphisms in indigenous and non-indigenous populations in Brazil.
Heinrich MM; Zembrzuski VM; Ota MM; Sacchi FP; Teixeira RL; Cabello Acero PH; Cunha GM; Souza-Santos R; Croda J; Basta PC
Tuberculosis (Edinb); 2016 Dec; 101():15-24. PubMed ID: 27865386
[TBL] [Abstract][Full Text] [Related]
36. NAT2 genetic polymorphisms and anti-tuberculosis drug-induced hepatotoxicity in Chinese community population.
Lv X; Tang S; Xia Y; Zhang Y; Wu S; Yang Z; Li X; Tu D; Chen Y; Deng P; Ma Y; Chen D; Chen R; Zhan S
Ann Hepatol; 2012; 11(5):700-7. PubMed ID: 22947533
[TBL] [Abstract][Full Text] [Related]
37. The role of cigarette smoking and liver enzymes polymorphisms in anti-tuberculosis drug-induced hepatotoxicity in Brazilian patients.
Zaverucha-do-Valle C; Monteiro SP; El-Jaick KB; Rosadas LA; Costa MJ; Quintana MS; de Castro L
Tuberculosis (Edinb); 2014 May; 94(3):299-305. PubMed ID: 24793319
[TBL] [Abstract][Full Text] [Related]
38. Expression of NAT2 in immune system cells and the relation of NAT2 gene polymorphisms in the anti-tuberculosis therapy in Mexican mestizo population.
Salazar-González R; Gómez R; Romano-Moreno S; Medellín-Garibay S; Núñez-Ruíz A; Magaña-Aquino M; Milán-Segovia RC; Portales-Pérez DP
Mol Biol Rep; 2014 Dec; 41(12):7833-43. PubMed ID: 25163630
[TBL] [Abstract][Full Text] [Related]
39. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis.
Huang YS; Chern HD; Su WJ; Wu JC; Lai SL; Yang SY; Chang FY; Lee SD
Hepatology; 2002 Apr; 35(4):883-9. PubMed ID: 11915035
[TBL] [Abstract][Full Text] [Related]
40. Determining the relation between N-acetyltransferase-2 acetylator phenotype and antituberculosis drug induced hepatitis by molecular biologic tests.
Bozok Cetintaş V; Erer OF; Kosova B; Ozdemir I; Topçuoğlu N; Aktoğu S; Eroğlu Z
Tuberk Toraks; 2008; 56(1):81-6. PubMed ID: 18330759
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
